| Name | Title | Contact Details |
|---|
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Baxter International Inc. is a Fortune 500 American health care company with headquarters in Deerfield, Illinois.
The Macroflux Corp. is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Family medicine, primary care, and dental service provider for the underserved and uninsured communities of Pinellas County.
We offer medical, dental and behavioral health care for Alameda Countys underserved Asian and Pacific Islander community.